Takuo Mizukami

Takuo Mizukami

Auto-generated profile, based on publicly available information

Takuo Mizukami

Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases , Tokyo

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2010 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
RTRamin Tehranchi
Ramin Tehranchi
PWPetter S. Woll
Petter S. Woll
KAKristina Anderson
Kristina Anderson
NBNatalija Buza-Vidas
Natalija Buza-Vidas
TMTakuo Mizukami
Takuo Mizukami
SJSten Eirik W. Jacobsen
Sten Eirik W. Jacobsen
The in vivo clinical significance of malignant stem cells remains unclear. Patients who have the 5q deletion (del[5q]) myelodysplastic syndrome (interstitial deletions involving the long arm of chromosome 5) have complete clinical and cytogenetic remissions in response to lenalidomide treatment, but they often have relapse. To determine whether the persistence of rare but distinct malignant stem cells accounts for such relapses, we examined bone marrow specimens obtained from seven patients with the del(5q) myelodysplastic syndrome who became transfusion-independent while receiving lenalidomide treatment and entered cytogenetic remission. Virtually all CD34+, CD38+ progenitor cells and stem cells that were positive for CD34 and CD90, with undetectable or low CD38 (CD38−/low), had the 5q deletion before treatment. Although lenalidomide efficiently reduced these progenitors in patients in complete remission, a larger fraction of the minor, quiescent, CD34+,CD38−/low, CD90+ del(5q) stem cells as well as functionally defined del(5q) stem cells remained distinctly resistant to lenalidomide. Over time, lenalidomide resistance developed in most of the patients in partial and complete remission, with recurrence or expansion of the del(5q) clone and clinical and cytogenetic progression. In these patients with the del(5q) myelodysplastic syndrome, we identified rare and phenotypically distinct del(5q) myelodysplastic syndrome stem cells that were also selectively resistant to therapeutic targeting at the time of complete clinical and cytogenetic remission. (Funded by the EuroCancerStemCell Consortium and others.)

19 February 2012 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SLSidinh Luc
Sidinh Luc
TLTiago C Luis
Tiago C Luis
HBHanane Boukarabila
Hanane Boukarabila
IMIain C Macaulay
Iain C Macaulay
NBNatalija Buza-Vidas
Natalija Buza-Vidas
SJSten Eirik W Jacobsen
Sten Eirik W Jacobsen
The commitment stage at which progenitors seed the thymus remains unclear. Jacobsen and colleagues show that the earliest progenitors in the neonatal thymus have combined myeloid, T lymphocyte and B lymphocyte potential but not megakaryocyte-erythroid potential. The stepwise commitment from hematopoietic stem cells in the bone marrow to T lymphocyte–restricted progenitors in the thymus represents a paradigm for understanding the requirement for distinct extrinsic cues during different stages of lineage restriction from multipotent to lineage-restricted progenitors. However, the commitment stage at which progenitors migrate from the bone marrow to the thymus remains unclear. Here we provide functional and molecular evidence at the single-cell level that the earliest progenitors in the neonatal thymus had combined granulocyte-monocyte, T lymphocyte and B lymphocyte lineage potential but not megakaryocyte-erythroid lineage potential. These potentials were identical to those of candidate thymus-seeding progenitors in the bone marrow, which were closely related at the molecular level. Our findings establish the distinct lineage-restriction stage at which the T cell lineage–commitment process transits from the bone marrow to the remote thymus.

3 October 2016 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TLTiago C Luis
Tiago C Luis
SLSidinh Luc
Sidinh Luc
TMTakuo Mizukami
Takuo Mizukami
HBHanane Boukarabila
Hanane Boukarabila
STSupat Thongjuea
Supat Thongjuea
SJSten Eirik W Jacobsen
Sten Eirik W Jacobsen

8 March 2012 in Blood
Verified
Journal Article
Open access
PDF file
MKMadoka Kuramitsu
Madoka Kuramitsu
ASAiko Sato-Otsubo
Aiko Sato-Otsubo
TMTomohiro Morio
Tomohiro Morio
MTMasatoshi Takagi
Masatoshi Takagi
TTTsutomu Toki
Tsutomu Toki
IHIsao Hamaguchi
Isao Hamaguchi
Fifty percent of Diamond-Blackfan anemia (DBA) patients possess mutations in genes coding for ribosomal proteins (RPs). To identify new mutations, we investigated large deletions in the RP genes RPL5, RPL11, RPL35A, RPS7, RPS10, RPS17, RPS19, RPS24, and RPS26. We developed an easy method based on quantitative-PCR in which the threshold cycle correlates to gene copy number. Using this approach, we were able to diagnose 7 of 27 Japanese patients (25.9%) possessing mutations that were not detected by sequencing. Among these large deletions, similar results were obtained with 6 of 7 patients screened with a single nucleotide polymorphism array. We found an extensive intragenic deletion in RPS19, including exons 1-3. We also found 1 proband with an RPL5 deletion, 1 patient with an RPL35A deletion, 3 with RPS17 deletions, and 1 with an RPS19 deletion. In particular, the large deletions in the RPL5 and RPS17 alleles are novel. All patients with a large deletion had a growth retardation phenotype. Our data suggest that large deletions in RP genes comprise a sizable fraction of DBA patients in Japan. In addition, our novel approach may become a useful tool for screening gene copy numbers of known DBA genes.

24 September 2009 in Blood
Verified
Journal Article
Open access
PDF file
JYJumpei Yamazaki
Jumpei Yamazaki
TMTakuo Mizukami
Takuo Mizukami
KTKazuya Takizawa
Kazuya Takizawa
MKMadoka Kuramitsu
Madoka Kuramitsu
HMHaruka Momose
Haruka Momose
KYKazunari Yamaguchi
Kazunari Yamaguchi
Adult T-cell leukemia/lymphoma (ATL) is a malignant lymphoproliferative disorder caused by HTLV-I infection. In ATL, chemotherapeutic responses are generally poor, which has suggested the existence of chemotherapy-resistant cancer stem cells (CSCs). To identify CSC candidates in ATL, we have focused on a Tax transgenic mouse (Tax-Tg) model, which reproduces ATL-like disease both in Tax-Tg animals and also after transfer of Tax-Tg splenic lymphomatous cells (SLCs) to nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Using a limiting dilution transplantation, it was estimated that one CSC existed per 104 SLCs (0.01%). In agreement with this, we have successfully identified candidate CSCs in a side population (0.06%), which overlapped with a minor population of CD38−/CD71−/CD117+ cells (0.03%). Whereas lymphoma did not develop after transplantation of 102 SLCs, 102 CSCs could consistently regenerate the original lymphoma. In addition, lymphoma and CSCs could also be demonstrated in the bone marrow and CD117+ CSCs were observed in both osteoblastic and vascular niches. In the CSCs, Tax, Notch1, and Bmi1 expression was down-regulated, suggesting that the CSCs were derived from Pro-T cells or early hematopoietic progenitor cells. Taken together, our data demonstrate that CSCs certainly exist and have the potential to regenerate lymphoma in our mouse model.

1 February 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
MKMadoka Kuramitsu
Madoka Kuramitsu
KOKazu Okuma
Kazu Okuma
MYMakoto Yamagishi
Makoto Yamagishi
TYTadanori Yamochi
Tadanori Yamochi
SFSanaz Firouzi
Sanaz Firouzi
IHIsao Hamaguchi
Isao Hamaguchi
Quantitative PCR (qPCR) for human T-lymphotropic virus 1 (HTLV-1) is useful for measuring the amount of integrated HTLV-1 proviral DNA in peripheral blood mononuclear cells. Many laboratories in Japan have developed different HTLV-1 qPCR methods. However, when six independent laboratories analyzed the proviral load of the same samples, there was a 5-fold difference in their results. To standardize HTLV-1 qPCR, preparation of a well-defined reference material is needed. We analyzed the integrated HTLV-1 genome and the internal control (IC) genes of TL-Om1, a cell line derived from adult T-cell leukemia, to confirm its suitability as a reference material for HTLV-1 qPCR. Fluorescent in situ hybridization (FISH) showed that HTLV-1 provirus was monoclonally integrated in chromosome 1 at the site of 1p13 in the TL-Om1 genome. HTLV-1 proviral genome was not transferred from TL-Om1 to an uninfected T-cell line, suggesting that the HTLV-1 proviral copy number in TL-Om1 cells is stable. To determine the copy number of HTLV-1 provirus and IC genes in TL-Om1 cells, we used FISH, digital PCR, and qPCR. HTLV-1 copy numbers obtained by these three methods were similar, suggesting that their results were accurate. Also, the ratio of the copy number of HTLV-1 provirus to one of the IC genes, RNase P, was consistent for all three methods. These findings indicate that TL-Om1 cells are an appropriate reference material for HTLV-1 qPCR.